期刊
FRONTIERS IN CELLULAR NEUROSCIENCE
卷 10, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fncel.2016.00052
关键词
glial cells; oligodendrocyte; proteomics; schizophrenia; pharmacology; clozapine; MK801
资金
- Sao Paulo Research Foundation (FAPESP) [13/08711-3, 14/21035-0, 14/14881-1, 14/10068-4]
- Brazilian National Council for Scientific and Technological Development (CNPq) [460289/2014-4]
- Research Fund (FAEPEX) from University of Campinas [0986/14]
- Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [14/21035-0, 14/14881-1, 13/08711-3, 14/10068-4] Funding Source: FAPESP
Separate lines of evidence have demonstrated the involvement of N-methyl-D-aspartate (NMDA) receptor and oligodendrocyte dysfunctions in schizophrenia. Here, we have carried out shotgun mass spectrometry proteome analysis of oligodendrocytes treated with the NMDA receptor antagonist MK-801 to gain potential insights into these effects at the molecular level. The MK-801 treatment led to alterations in the levels of 68 proteins, which are associated with seven distinct biological processes. Most of these proteins are involved in energy metabolism and many have been found to be dysregulated in previous proteomic studies of post-mortem brain tissues from schizophrenia patients. Finally, addition of the antipsychotic clozapine to MK-801 treated oligodendrocyte cultures resulted in changes in the levels of 45 proteins and treatment with clozapine alone altered 122 proteins and many of these showed opposite changes to the MK-801 effects. Therefore, these proteins and the associated energy metabolism pathways should be explored as potential biomarkers of antipsychotic efficacy. In conclusion, MK-801 treatment of oligodendrocytes may provide a useful model for testing the efficacy of novel treatment approaches.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据